When visiting a pharmacy, you may be presented with a coupon for your prescription medications. While this might seem like an appealing opportunity to save a significant amount of money, particularly for those with insurance, the decision to accept such coupons is not straightforward.
A recent study published on April 6 in the Journal of the American Medical Association reveals that, despite rising prescription drug prices, the utilization of manufacturer-sponsored coupons among patients with commercial insurance has noticeably declined over the past few years. Lead author So-Yeon Kang, an assistant professor of health management and policy at Georgetown University, noted that while manufacturers continue to provide a steady supply of coupons, many insured individuals still face affordability challenges.
According to Kang, patients find themselves caught in a complex situation involving both insurance providers and drug manufacturers. Typically, these manufacturers distribute copay coupon cards, which can be obtained online or directly at the pharmacy. It is important to distinguish these coupons from discount card services like GoodRx, which negotiate bulk prices for medications and pass those savings on to consumers.
The primary intent of these coupons is to maintain the competitiveness of brand-name drugs by offering patients immediate financial relief. This often leads consumers to opt for more expensive brand-name medications instead of opting for less costly generic alternatives that may be available.
Insurance companies argue that this practice places an unfair financial burden on them, resulting in higher monthly premiums for consumers. They contend that the increased costs ultimately affect patients rather than the drug manufacturers themselves.
So, should you take advantage of prescription drug coupons when they are offered? The answer isn’t straightforward and depends on several factors.
For uninsured individuals, utilizing a coupon can be an effective way to lower prescription costs, especially in cases where no generic equivalent exists. TrumpRx, a new federally funded initiative, serves as a dashboard for prescription drug coupons. This platform features both manufacturer coupons and others, offering potential savings for consumers, particularly in the short term. Michelle Long, a senior policy manager at KFF, which conducts research and polling on health policy, emphasized that uninsured patients could find significant savings through TrumpRx or manufacturer coupons, despite the platform currently listing only around 85 drugs approved by the FDA. It is essential to understand that these coupons have limitations and are not a permanent solution; once they are exhausted, uninsured consumers may need to pay full price for their medications.
For those with commercial health insurance, the situation becomes more complex. If the prescribed medication is not covered by your insurance or if you plan to pay out-of-pocket, then using the coupon may be beneficial. However, caution is warranted if your insurance does cover the drug. Kang’s research indicates that the usage of coupons for obesity medications among commercially insured patients plummeted from 54.6% in 2017 to just 2.5% in 2024, despite the increasing availability of these drugs. This decline reflects a trend where more patients opt to pay cash for their medications as prices have dropped, coupled with insurers’ reluctance to provide coverage and a shift in focus by manufacturers from coupon distribution to marketing efforts.
If you have insurance and expect to meet your annual deductible through various health care expenses, using coupons might help reduce your immediate out-of-pocket costs. However, be aware that the value of the coupon typically does not contribute toward your deductible. It is advisable to use a coupon only when no generic option is available and when you are confident you will meet your deductible threshold.
In most cases, it is advisable not to use the coupon. Unless the medication is not covered by your plan, relying on coupons may lead to higher indirect costs. It is often more beneficial to contribute towards your deductible instead.
Furthermore, pay attention to copay adjustment programs that insurers may implement to discourage the use of drug coupons. These programs often take two forms, as described by Long. “Copay accumulators” permit the full value of drug coupons to be used but do not allow this amount to count towards deductibles or out-of-pocket maximums, making it more challenging for patients to reach the point where insurance begins to cover their prescriptions and other health care services. As a result, patients might find themselves paying the full price of their medications after failing to meet their annual deductible.
“Copay maximizers” function similarly, ensuring that coupon values do not contribute to deductibles. These programs may involve third-party adjustments to patient copayments throughout the year to align with the amount provided by manufacturer coupons. Insurers often market these programs under favorable names like “Employee Savings Program,” which may sound beneficial but, in reality, diminish the actual value of the coupons, according to Long.
Initially, consumers may perceive savings at the pharmacy, but they could end up facing higher costs over time. It is also noteworthy that Medicare and Medicaid recipients are prohibited from using manufacturer-sponsored coupons due to federal anti-kickback laws, which restrict offering anything of value to influence purchasing decisions related to federally funded health care programs.
